l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease
l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapeutic agent for Parkinson's disease (PD). l-DOPA is traditionally believed to be an inert amino acid that exerts actions and effectiveness in PD through its conversion to dopamine. In contrast to this generally accepted idea, l-D...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2019-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_d9d086c0989f499aac572dde4c3cfa84 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Yoshio Goshima |e author |
| 700 | 1 | 0 | |a Daiki Masukawa |e author |
| 700 | 1 | 0 | |a Yuka Kasahara |e author |
| 700 | 1 | 0 | |a Tatsuo Hashimoto |e author |
| 700 | 1 | 0 | |a Aderemi Caleb Aladeokin |e author |
| 245 | 0 | 0 | |a l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease |
| 260 | |b Frontiers Media S.A., |c 2019-10-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2019.01119 | ||
| 520 | |a l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapeutic agent for Parkinson's disease (PD). l-DOPA is traditionally believed to be an inert amino acid that exerts actions and effectiveness in PD through its conversion to dopamine. In contrast to this generally accepted idea, l-DOPA is proposed to be a neurotransmitter. Recently, GPR143 (OA1), the gene product of ocular albinism 1 was identified as a receptor candidate for l-DOPA. GPR143 is widely expressed in the central and peripheral nervous system. GPR143 immunoreactivity was colocalized with phosphorylated α-synuclein in Lewy bodies in PD brains. GPR143 may contribute to the therapeutic effectiveness of l-DOPA and might be related to pathogenesis of PD. | ||
| 546 | |a EN | ||
| 690 | |a l-DOPA | ||
| 690 | |a neurotransmitter | ||
| 690 | |a G protein-coupled receptor | ||
| 690 | |a Parkinson's disease | ||
| 690 | |a dopamine | ||
| 690 | |a Lewy bodies | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 10 (2019) | |
| 787 | 0 | |n https://www.frontiersin.org/article/10.3389/fphar.2019.01119/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/d9d086c0989f499aac572dde4c3cfa84 |z Connect to this object online. |